AlphaCentric Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

AlphaCentric Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$811K	Buy	+17,000	New	+$760K	0.24%	43

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

AlphaCentric Advisors's TPTX Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021: 17,000 shares worth $811K. The stake represents 0.24% of the portfolio and ranks #43 among its holdings.

172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

AlphaCentric Advisors held 17,000 shares of Turning Point Therapeutics, Inc. Common Stock worth $811K as of Q4 2021.
Turning Point Therapeutics, Inc. Common Stock was a new AlphaCentric Advisors position in Q4 2021.
Turning Point Therapeutics, Inc. Common Stock made up 0.24% of AlphaCentric Advisors's portfolio in Q4 2021, its #43 holding.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.